Olema Pharmaceuticals/OLMA

$10.86

-5.97%
-
1D1W1MYTD1YMAX

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis. It is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Ticker

OLMA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sean Bohen

Employees

74

Headquarters

San francisco, United States
Website
olema.com

OLMA Metrics

BasicAdvanced
$645.82M
Market cap
-
P/E ratio
-$2.16
EPS
2.09
Beta
-
Dividend rate
$645.82M
2.09337
$17.79
$3.53
790.17K
12.327
-39.24%
-42.82%
-42.54%
2.502
2.544
17.59%

What the Analysts think about OLMA

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 8 analysts.
127.9% upside
High $30.00
Low $20.00
$10.86
Current price
$24.75
Average price target

OLMA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-26.7M
24.19%
Profit margin
0%
-

OLMA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 1.89%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.70
-$0.49
-$0.48
-$0.49
-
Expected
-$0.66
-$0.73
-$0.51
-$0.48
-$0.54
Surprise
5.53%
-32.61%
-6.11%
1.89%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Olema Pharmaceuticals stock?

Olema Pharmaceuticals (OLMA) has a market cap of $645.82M as of April 13, 2024.

What is the P/E ratio for Olema Pharmaceuticals stock?

The price to earnings (P/E) ratio for Olema Pharmaceuticals (OLMA) stock is 0 as of April 13, 2024.

Does Olema Pharmaceuticals stock pay dividends?

No, Olema Pharmaceuticals (OLMA) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Olema Pharmaceuticals dividend payment date?

Olema Pharmaceuticals (OLMA) stock does not pay dividends to its shareholders.

What is the beta indicator for Olema Pharmaceuticals?

Olema Pharmaceuticals (OLMA) has a beta rating of 2.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Olema Pharmaceuticals stock price target?

The target price for Olema Pharmaceuticals (OLMA) stock is $24.75, which is 127.9% above the current price of $10.86. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Olema Pharmaceuticals stock

Buy or sell Olema Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing